

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Oxethazaine
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Tepilta® Versus Oxetacaine, Antacids and Placebo
Details : Oxetacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2011
Lead Product(s) : Oxethazaine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
